Portal de investigación
Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML).
Fecha de publicación:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Dinardo, Courtney Denton
- Schuh, Andre C.
- Papayannidis, Cristina
- Vyas, Paresh
- Wei, Andrew H.
- Zeidan, Amer Methqal
- Chen, Clara
- Lord-Bessen, Jennifer
- Yu, Peiwen
- Shi, Ling
- Guo, Shien
- Bluemmert, Iryna
- Yu, Xin
- Hasan, Maroof
- Regueira, Patricia Martin
- De Botton, Stephane
Grupos
Abstract
Abstract no disponible
Filiaciones
Filiaciones no disponibles
Campos de Estudio
Cita
Dinardo,CD,Montesinos,P,Schuh,AC,Papayannidis,C,Vyas,P,Wei,AH,Zeidan,AM et al. Health-related quality of life (HRQoL) with enasidenib versus conventional care regimens in older patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia (R/R AML). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO). 2022. ELECTR NETWORK-JUN 03-07. TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103:LIPPINCOTT WILLIAMS & WILKINS. 2022.